GLP1R and atherosclerosis: Indeed, several experimental studies have revealed that incretin-based treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, significantly suppress the development of atherosclerosis in animal models [4]–[8].